

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	Not yet assigned
				Filing Date	On even date herewith
				First Named Inventor	Masahiko TAMURA
				Parent Group Art Unit	1653
				Parent Examiner Name	C. S. F. Low
Sheet	1	of	2	Attorney Docket Number	TAMURA=4A
				USPTO 10/026496 JC973	12/27/01

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known	
Application Number	Not yet assigned
Filing Date	On even date herewith
First Named Inventor	Masahiko TAMURA
Parent Group Art Unit	1653
Parent Examiner	C. S.F. Low

Attorney Docket Number

Tamura=4A

JC973 10/026696
U.S. PTO
12/27/01

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AF	BENIGNI, et al; "Inhibition of Human Platelet Aggregation by Parathyroid Hormone"; <i>Am. J. Nephrol</i> , 5:243-247 (1985).	
	AG	BRICKMAN et al; "Parathyroid Hormone, Platelet Calcium, and Blood Pressure in Normotensive Subjects"; <i>Hypertension</i> , Vol. 18, No. 2, pp. 176-182, 1991.	
	AH	Stedmann's Medical Dictionary, 26 th Ed.; M. Spraycar, editor, William & Wilkins, Baltimore, 1995.	
	AI	MEYTES, et al; "Effect of Parathyroid Hormone on Erythropoiesis"; <i>J. Clin. Invest.</i> 67:1263-1269; 1981.	
	AJ	HOKOM et al; "Pegylated Megakaryocyte Growth and Development Factor Abrogates the Lethal Thrombocytopenia Associated with Carboplatin and Irradiation in Mice"; <i>Blood</i> , 86: No. 12, 4486-4492, 1995.	
	AK	HERODIN et al; "Recombinant Glycosylated Human Interleukin-6 Accelerates Peripheral Blood Platelet Count Recovery in Radiation-Induced Bone Marrow Depression in Baboons"; <i>Blood</i> , Vol. 80, No. 3, pp. 688-695; 1992.	
	AL	WALLACE et al; "Thrombocytopoietic Properties of Oncostatin M"; <i>Blood</i> ; Vol. 86, No. 4, pp. 1310-1315; 1995.	
	AM	LEONARD et al; "Recombinant Human Interleukin-11 Stimulates Multilineage Hematopoietic Recovery in Mice After a Myelosuppressive Regimen of Sublethal Irradiation and Carboplatin"; <i>Blood</i> ; Vol. 83, No. 6; pp. 1499-1506; 1994.	
	AN	SHIVDASANI et al; "Transcription Factor NF-E2 is Required for Platelet Formation Independent of the Actions of Thrombopoietin MGDF in Megakaryocyte Development"; <i>Cell</i> ; Vol. 81, pp. 695-704, 1995.	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.